Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Spinal Muscular Atrophy | Study Protocol

The RESISTANT study (Respiratory Muscle Training in Patients with Spinal Muscular Atrophy): study protocol for a randomized controlled trial

Authors: Kim Kant-Smits, Bart Bartels, Fay-Lynn Asselman, Esther S. Veldhoen, Ruben P. A. van Eijk, W. Ludo van der Pol, Erik H. J. Hulzebos

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Spinal Muscular Atrophy (SMA) is characterized by progressive and predominantly proximal and axial muscle atrophy and weakness. Respiratory muscle weakness results in impaired cough with recurrent respiratory tract infections, nocturnal hypoventilation, and may ultimately lead to fatal respiratory failure in the most severely affected patients. Treatment strategies to either slow down the decline or improve respiratory muscle function are wanting.

Objective

The aim of this study is to assess the feasibility and efficacy of respiratory muscle training (RMT) in patients with SMA and respiratory muscle weakness.

Methods

The effect of RMT in patients with SMA, aged ≥ 8 years with respiratory muscle weakness (maximum inspiratory mouth pressure [PImax] ≤ 80 Centimeters of Water Column [cmH2O]), will be investigated with a single blinded randomized sham-controlled trial consisting of a 4-month training period followed by an 8-month open label extension phase.

Intervention

The RMT program will consist of a home-based, individualized training program involving 30-breathing cycles through an inspiratory and expiratory muscle training device. Patients will be instructed to perform 10 training sessions over 5–7 days per week. In the active training group, the inspiratory and expiratory threshold will be adjusted to perceived exertion (measured on a Borg scale). The sham-control group will initially receive RMT at the same frequency but against a constant, non-therapeutic resistance. After four months the sham-control group will undergo the same intervention as the active training group (i.e., delayed intervention). Individual adherence to the RMT protocol will be reviewed every two weeks by telephone/video call with a physiotherapist.

Main study parameters/endpoints

We hypothesize that the RMT program will be feasible (good adherence and good acceptability) and improve inspiratory muscle strength (primary outcome measure) and expiratory muscle strength (key secondary outcome measure) as well as lung function, patient reported breathing difficulties, respiratory infections, and health related quality of life (additional secondary outcome measures, respectively) in patients with SMA.

Discussion

RMT is expected to have positive effects on respiratory muscle strength in patients with SMA. Integrating RMT with recently introduced genetic therapies for SMA may improve respiratory muscle strength in this patient population.

Trial registration

Retrospectively registered at clinicaltrial.gov: NCT05632666.
Literature
1.
Wadman R, Vrancken A, van den Berg L, van der Pol W. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Am Acad Neurol. 2012;79:2050–5.
2.
Finkel RE, Sejersen T, Mercuri E, Study W, Bertini E. 218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA. Neuromuscul Disord. 2017;27(6):596–605.PubMedCrossRef
3.
4.
5.
Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):1–15.CrossRef
6.
Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027–49.PubMedCrossRef
7.
Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, et al. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial). BMJ Open. 2018;8: e019932.PubMedPubMedCentralCrossRef
8.
Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, et al. Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology. 2018;91(13):E1206–14.PubMedPubMedCentralCrossRef
9.
Bartels B, Habets L, Stam M, Wadman R, Wijngaarde C, Schoenmakers M, et al. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurol. 2019;19:1–10.CrossRef
10.
Bartels B, De Groot JF, Habets LE, Wijngaarde CA, Vink W, Stam M, et al. Fatigability in spinal muscular atrophy: Validity and reliability of endurance shuttle tests. Orphanet J Rare Dis. 2020;15(1):1–9.CrossRef
11.
Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c–4. Eur J Neurol. 2018;25(3):512–8.PubMedCrossRef
12.
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723–32.PubMedCrossRef
13.
Paul GR, Gushue C, Kotha K, Shell R. The respiratory impact of novel therapies for spinal muscular atrophy. Pediatr Pulmonol. 2021:56(4):687-796.
14.
Heitschmidt L, Pichlmaier L, Eckerland M, Steindor M, Olivier M, Fuge I, et al. Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy – a single-center retrospective study. Eur J Paediatr Neurol. 2021;31:88–91.PubMedCrossRef
15.
Audic F, De La Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J, Barnerias C, et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15(1):1–10.CrossRef
16.
Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Eur J Paediatr Neurol. 2022;39(March):1–10.PubMedCrossRef
17.
Koessler W, Wanke T, Winkler G, Nader A, Toifl K, Kurz H, et al. 2 Years’ experience with inspiratory muscle training in patients with neuromuscular disorders. Chest. 2001;120(3):765–9.PubMedCrossRef
18.
Winkler G, Zifko U, Nader A, Frank W, Zwick H, Toifl K, et al. Dose-dependent effects of inspiratory muscle training in neuromuscular disorders. Muscle Nerve. 2000;23(8):1257–60.PubMedCrossRef
19.
DiMarco AF, Kelling JS, DiMarco MS, Jacobs I, Shields R, Altose MD. The effects of inspiratory resistive training on respiratory muscle function in patients with muscular dystrophy. Muscle Nerve. 1985;8(4):284–90.PubMedCrossRef
20.
Gozal D, Thiriet P. Respiratory muscle training in neuromuscular disease: long-term effects on strength and load perception. Med Sci Sports Exerc. 1999;31(11):1522–7.PubMedCrossRef
21.
Aslan GK, Gurses HN, Issever H, Kiyan E. Effects of respiratory muscle training on pulmonary functions in patients with slowly progressive neuromuscular disease: a randomized controlled trial. Clin Rehabil. 2014;28(6):573–81.PubMedCrossRef
22.
Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med. 2003;168(1):10–48.PubMedCrossRef
23.
Wanke T, Toifl K, Merkle M, Formanek D, Lahrmann H, Zwick H. Inspiratory muscle training in patients with Duchenne muscular dystrophy. Chest. 1994;105(2):475–82.PubMedCrossRef
24.
Harver A, Mahler DA, Daubenspeck JA. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1989;111(2):117–24.PubMedCrossRef
25.
Keens TG, Krastins IRB, Wannamaker EM, Levison H, Crozier DN, Bryan AC. Ventilatory muscle endurance training in normal subjects and patients with cystic fibrosis. Am Rev Respir Dis. 1977;116(5):853–60.PubMed
26.
Hornstein S, Inman S, Ledsome JR. Ventilatory muscle training in kyphoscoliosis. Spine (Phila Pa 1976). 1987;12(9):859–63.PubMedCrossRef
27.
Human A, Morrow B. Inspiratory muscle training in children and adolescents living with neuromuscular diseases: a pre-experimental study. S Afr J Physiother. 2021;77(1):1–10.CrossRef
28.
Wadman RI, Stam M, Gijzen M, Lemmink HH, Snoeck IN, Wijngaarde CA, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. J Neurol Neurosurg Psychiatry. 2017;88(4):364–7.CrossRef
29.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. Spirit 2013 statement: Defining standard protocol items for clinical trials. Chin J Evid Based Med. 2013;13(12):1501–7.
30.
Silva I, Pedrosa R, Azevedo A, Forbes A, Fregonezi G, Dourado Junior M, et al. Respiratory muscle training in children and adults with neuromuscular disease (Review). Cochrane Database Syst Rev. 2019;9(9):CD011711.PubMed
31.
Veldhoen ES, Wijngaarde CA, Hulzebos EHJ, Wösten-van Asperen RM, Wadman RI, van Eijk RPA, et al. Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet J Rare Dis. 2022;17(1):70.PubMedPubMedCentralCrossRef
32.
Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J. 2019;53:1801214.PubMedCrossRef
33.
34.
McDonald T, Stiller K. Inspiratory muscle training is feasible and safe for patients with acute spinal cord injury. J Spinal Cord Med. 2019;42(2):220–7.PubMedCrossRef
35.
Menzes K, Nascimento L, Avelino P, Polese J, Salmela L. A review on respiratory muscle training devices. J Pulm Respir Med. 2018;08(02):451.
36.
Suzuki S, Sato M, Okubo T. Expiratory muscle training and sensation of respiratory effort during exercise in normal subjects. Thorax. 1995;50(4):366–70.PubMedPubMedCentralCrossRef
37.
Matsuo Y, Yanagisawa Y, Cahalin LP. Brief research report: the feasibility of expiratory resistive loading using the threshold inspiratory muscle training device. Cardiopulm Phys Ther J. 2014;25(3):92–5.CrossRef
38.
39.
Schoenmakers MAGC, Gulmans VAM, Gooskens RHJM, Helders PJM. Spina bifida at the sacral level: More than minor gait disturbances. Clin Rehabil. 2004;18(2):178–85.PubMedCrossRef
40.
Wilson SH, Cooke NT, Edwards RHT, Spiro SG. Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax. 1984;39:535–8.PubMedPubMedCentralCrossRef
41.
Aaronson NK, Muller M, Cohen PDA, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol. 1998;51(11):1055–68.PubMedCrossRef
42.
43.
Bastiaansen D, Koot HM, Bongers IL, Varni JW, Verhulst FC. Measuring quality of life in children referred for psychiatric problems: Psychometric properties of the PedsQLTM 4.0 generic core scales. Qual Life Res. 2004;13(2):489–95.PubMedCrossRef
44.
Mellies U, Stehling F, Dohna-Schwake C. Normal values for inspiratory muscle function in children. Physiol Meas. 2014;35(10):1975–81.PubMedCrossRef
45.
Hall GL, Filipow N, Ruppel G, Okitika T, Thompson B, Kirkby J, et al. Official ERS technical standard: global lung function initiative reference values for static lung volumes in individuals of european ancestry. Eur Respir J. 2021;57(3):2000289.PubMedCrossRef
46.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multı-ethnic reference values for spirometry for the 3–95 year age range: the global lung function 2012 equations: report of the Global Lung Function Initiative (GLI), ERS task force to establish improved lung function reference values. Eur Respir J. 2012;40(6):1324–43.PubMedPubMedCentralCrossRef
47.
Koopman M, Zanen P, Kruitwagen CLJJ, Van Der Ent CK, Arets HGM. Reference values for paediatric pulmonary function testing: The Utrecht dataset. Respir Med. 2011;105(1):15–23.PubMedCrossRef
48.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.PubMedCrossRef
49.
Criée CP. Empfehlungen der Deutschen Atemwegsliga zur Messung der inspiratorischen Muskelfunktion. Pneumologie. 2003;57:98–100.PubMedCrossRef
50.
Madden AM, Tsikoura T, Stott DJ. The estimation of body height from ulna length in healthy adults from different ethnic groups. J Hum Nutr Diet. 2012;25(2):121–8.PubMedCrossRef
51.
Fletcher CM, Clifton M, Fairbairn AS, Fry J, Gilson C, Higgings ITT, et al. Standardized questionnaire on respiratory symptoms. Br Med J. 1960;1665.
52.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–6.PubMedPubMedCentralCrossRef
53.
54.
Fayssoil A, Behin A, Ogna A, Mompoint D, Amthor H, Clair B, et al. Diaphragm: Pathophysiology and Ultrasound Imaging in Neuromuscular Disorders. J Neuromuscul Dis. 2018;5(1):1–10.PubMedPubMedCentralCrossRef
55.
Boentert M, Wenninger S, Sansone VA. Respiratory involvement in neuromuscular disorders. Neuromuscul Dis Muscle. 2017;30(5):529–37.
56.
Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics. 2009;123(SUPPL. 4):245–50.CrossRef
57.
Human A, Corten L, Jelsma J, Morrow B. Inspiratory muscle training for children and adolescents with neuromuscular diseases: A systematic review. Neuromuscul Disord. 2017;27(6):503–17.PubMedCrossRef
58.
Kant-Smits K, Hulzebos EHJ, Habets LE, Asselman F, Veldhoen ES, van Eijk RPA, et al. Respiratory muscle fatigability in patients with spinal muscular atrophy. Pediatr Pulmonol. 2022;57:3050.PubMedPubMedCentralCrossRef
59.
Bulthuis M, van Empelen R, Heimeriks I, Dronkers J. Het gebruik van een belastingschaal bij kinderen tussen de 8 en 12 jaar voor het meten van subjectief ervaren belasting tijdens training. Nederlands tijdschrijft voor Kinderfysiotherapie. 2010;22(67):24–31.
60.
Robertson RJ, Goss FL, Boer NF, Peoples JA, Foreman AJ, Dabayebeh IM, et al. Children’s OMNI scale of perceived exertion: mixed gender and race validation. Med Sci Sports Exerc. 2000;32(2):452–8.PubMedCrossRef
61.
Just N, Bautin N, Danel-Brunaud V, Debroucker V, Matran R, Perez T. The Borg dyspnoea score: a relevant clinical marker of inspiratory muscle weakness in amyotrophic lateral sclerosis. Eur Respir J. 2010;35(2):353–60.PubMedCrossRef
Metadata
Title
The RESISTANT study (Respiratory Muscle Training in Patients with Spinal Muscular Atrophy): study protocol for a randomized controlled trial
Authors
Kim Kant-Smits
Bart Bartels
Fay-Lynn Asselman
Esther S. Veldhoen
Ruben P. A. van Eijk
W. Ludo van der Pol
Erik H. J. Hulzebos
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03136-3

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue

Research

Inpatient rehabilitation therapy in stroke patients with reperfusion therapy: a national prospective registry study

Case report

Pontine stroke in a patient with Chronic Progressive External Ophthalmoplegia (CPEO): a case report

Research

Relationship between mean blood pressure during hospitalization and clinical outcome after acute ischemic stroke

Research

Higher serum homocysteine levels are associated with an increased risk of hemorrhagic transformation in patients with acute ischemic stroke

Research

Social stigma and its relationship with quality of life in multiple sclerosis patients

Research

Plasma neurofilament light admission levels and development of axonal pathology in mild traumatic brain injury